About Atreus Pharmaceuticals
Atreus Pharmaceuticals is a company based in Ottawa (Canada) founded in 2007 was acquired by Advanced Accelerator Applications in January 2015. Atreus Pharmaceuticals has raised $6 million across 1 funding round from investors including Advanced Accelerator Applications. Atreus Pharmaceuticals operates in a competitive market with competitors including ImaginAb, AC Immune, HYCOR BioMedical, APRINOIA and Innovate Biopharma, among others.
- Headquarter Ottawa, Canada
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6 M (USD)
in 1 rounds
-
Latest Funding Round
$6 M (USD), Series A
Mar 02, 2010
- Investors
-
Employee Count
Not available
-
Acquired by
Advanced Accelerator Applications
(Jan 08, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Atreus Pharmaceuticals
Atreus Pharmaceuticals has successfully raised a total of $6M through 1 strategic funding round. The most recent funding activity was a Series A round of $6 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Atreus Pharmaceuticals
Atreus Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Advanced Accelerator Applications.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
Locked | Locked | Locked |
Investor details for Atreus Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Atreus Pharmaceuticals
Investment portfolio details for Atreus Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Atreus Pharmaceuticals
Detailed financials for Atreus Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Atreus Pharmaceuticals Comparisons
Peer comparison for Atreus Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Atreus Pharmaceuticals
Atreus Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, AC Immune, HYCOR BioMedical, APRINOIA and Innovate Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Developer of diagnostic instruments and reagents for autoimmune diseases and allergies
|
|
| Locked | Locked | Locked |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs and imaging agent for GI disorders
|
|
| Locked | Locked | Locked |
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
Detailed competitors of Atreus Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Atreus Pharmaceuticals
Complete news archive for Atreus Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atreus Pharmaceuticals
Atreus Pharmaceuticals was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Atreus Pharmaceuticals is headquartered in Ottawa, Canada. It is registered at Ottawa, Ontario, Canada.
Atreus Pharmaceuticals is a funded company, having raised a total of $6M across 1 funding round to date.
Atreus Pharmaceuticals was focussed on developing in-vivo radiopharmaceutical products for Nuclear Medicine (SPECT) imaging and for PET imaging. Its product line was based on the Annexin V human protein, which binds to phosphatidylserine, a molecule that only shows up on the surface of dead or dying cells. Its lead diagnostic product Annexin V-128 was in phase 12 trials for rheumatoid arthritis and ankylosing spondylitis. It also claims that the compound when used with the medical isotope Technetium-99, has the ability to be used to evaluate the response to treatment for lymphoma and lung cancer. In January 2015, Advanced Accelerator Applications (AAA) fully acquired Atreus.
Atreus Pharmaceuticals has 1 investor. Key investors include Advanced Accelerator Applications.